Restin: mutants, receptor cloning and signaling studies.
Restin:突变体、受体克隆和信号传导研究。
基本信息
- 批准号:7392415
- 负责人:
- 金额:$ 15.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-03 至 2010-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAngiogenesis InhibitorsAntineoplastic AgentsBindingBiochemicalC-terminalCell surfaceClone CellsCloningCollagenDrug resistanceEndothelial CellsEventHumanMediatingMolecular BiologyProteinsSignal TransductionStructure-Activity RelationshipTechniquesToxic effectcancer therapychemotherapymutantreceptorrestintumor
项目摘要
Anti-angiogenic molecules have tremendous potential in the treatment of cancer. Anti-angiogenic therapy has
several benefits over conventional chemotherapy as different tumors can be treated with less toxicity. Most significantly, drug resistance is unlikely. Despite these potential advantages, the utility of current anti-angiogenic agents is limited since the mechanism of action of these proteins is unknown. The PI?s long term objective is to study the mechanism of action of antiangiogenic proteins and to identify the cell surface molecules that interact with these proteins. This proposal focuses on Restin, a C-terminal fragment of the NC1 domain in human collagen XV. This fragment possesses antimigratory function against endothelial cells. This proposal plans to understand the mechanism of action of restin with the following specific aims:
Specific Aim 1: To define the structure-function relationship of restin.
Specific Aim 2: To determine the intracellular signaling events mediated by restin.
Specific Aim 3: To identify and clone the cell surface binding partner(s) receptor for restin.
We will use molecular biology and biochemical techniques to address these aims. Once the mechanism of restin?s action has been elucidated, we will understand better the utility of restin and similar agents as anti-cancer drugs.
抗血管生成分子在癌症治疗中具有巨大的潜力。抗血管生成疗法
与常规化疗相比有几个好处,因为不同的肿瘤可以以较低的毒性进行治疗。最重要的是,不太可能出现耐药性。尽管有这些潜在的优势,但目前的抗血管生成剂的效用是有限的,因为这些蛋白质的作用机制是未知的。私家侦探?的长期目标是研究抗血管生成蛋白的作用机制,并确定与这些蛋白相互作用的细胞表面分子。该提案的重点是Restin,人胶原XV中NC 1结构域的C-末端片段。该片段对内皮细胞具有抗迁移功能。该提案计划了解restin的作用机制,具体目标如下:
具体目标1:明确restin的结构与功能关系。
具体目标2:确定由restin介导的细胞内信号传导事件。
具体目标3:鉴定和克隆restin的细胞表面结合伴侣受体。
我们将使用分子生物学和生物化学技术来实现这些目标。一旦休息的机制?的作用已经阐明,我们将更好地了解restin和类似药物作为抗癌药物的效用。
项目成果
期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Syx, a RhoA guanine exchange factor, is essential for angiogenesis in Vivo.
- DOI:10.1161/circresaha.108.181388
- 发表时间:2008-09-26
- 期刊:
- 影响因子:20.1
- 作者:Garnaas MK;Moodie KL;Liu ML;Samant GV;Li K;Marx R;Baraban JM;Horowitz A;Ramchandran R
- 通讯作者:Ramchandran R
Expression pattern for unc5b, an axon guidance gene in embryonic zebrafish development.
unc5b 的表达模式,这是胚胎斑马鱼发育中的轴突引导基因。
- DOI:10.3727/000000006781510714
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Kaur,Sukhbir;Abu-Asab,MonesS;Abu-Abab,MonesS;Singla,Shobhit;Yeo,Sang-Yeob;Ramchandran,Ramani
- 通讯作者:Ramchandran,Ramani
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ramani Ramchandran其他文献
Ramani Ramchandran的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ramani Ramchandran', 18)}}的其他基金
Delta like-4 long non-coding RNA function in angiogenesis and vascular anomalies
Delta like-4长非编码RNA在血管生成和血管异常中的功能
- 批准号:
9265498 - 财政年份:2015
- 资助金额:
$ 15.97万 - 项目类别:
Delta like-4 long non-coding RNA function in angiogenesis and vascular anomalies
Delta like-4长非编码RNA在血管生成和血管异常中的功能
- 批准号:
9099891 - 财政年份:2015
- 资助金额:
$ 15.97万 - 项目类别:
Delta like-4 long non-coding RNA function in angiogenesis and vascular anomalies
Delta like-4长非编码RNA在血管生成和血管异常中的功能
- 批准号:
8919597 - 财政年份:2015
- 资助金额:
$ 15.97万 - 项目类别:
Targeting DUSP-5 to Treat Vascular Anomalies
靶向 DUSP-5 治疗血管异常
- 批准号:
8789333 - 财政年份:2012
- 资助金额:
$ 15.97万 - 项目类别:
Targeting DUSP-5 to Treat Vascular Anomalies
靶向 DUSP-5 治疗血管异常
- 批准号:
8602072 - 财政年份:2012
- 资助金额:
$ 15.97万 - 项目类别:
Targeting DUSP-5 to Treat Vascular Anomalies
靶向 DUSP-5 治疗血管异常
- 批准号:
8259361 - 财政年份:2012
- 资助金额:
$ 15.97万 - 项目类别:
Targeting DUSP-5 to Treat Vascular Anomalies
靶向 DUSP-5 治疗血管异常
- 批准号:
8431719 - 财政年份:2012
- 资助金额:
$ 15.97万 - 项目类别:
Snrk-1 and Dusp-5 co-ordinately regulate vascular development in vertebrates
Snrk-1 和 Dusp-5 协调调节脊椎动物的血管发育
- 批准号:
8701362 - 财政年份:2011
- 资助金额:
$ 15.97万 - 项目类别:
Snrk-1 and Dusp-5 co-ordinately regulate vascular development in vertebrates
Snrk-1 和 Dusp-5 协调调节脊椎动物的血管发育
- 批准号:
8191883 - 财政年份:2011
- 资助金额:
$ 15.97万 - 项目类别:
相似海外基金
Development of Novel Lung Cancer Therapy Using Tumor-Specific Angiogenesis Inhibitors and Drug Repositioning
使用肿瘤特异性血管生成抑制剂和药物重新定位开发新型肺癌疗法
- 批准号:
21H03019 - 财政年份:2021
- 资助金额:
$ 15.97万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of biomarkers related to drug resistance of angiogenesis inhibitors
血管生成抑制剂耐药性相关生物标志物的开发
- 批准号:
20K08542 - 财政年份:2020
- 资助金额:
$ 15.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Structural and Functional Studies of Brain Angiogenesis Inhibitors (BAIs/ADGRBs)
脑血管生成抑制剂 (BAIs/ADGRB) 的结构和功能研究
- 批准号:
9813883 - 财政年份:2019
- 资助金额:
$ 15.97万 - 项目类别:
Elucidation of proteinuria expression mechanism by angiogenesis inhibitors and research on adverse effect avoidance
血管生成抑制剂蛋白尿表达机制的阐明及不良反应避免的研究
- 批准号:
17K08457 - 财政年份:2017
- 资助金额:
$ 15.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of cardiotoxicity and elucidation of cardiotoxic molecular mechanisms in cancer patients receiving angiogenesis inhibitors
接受血管生成抑制剂的癌症患者的心脏毒性评估和心脏毒性分子机制的阐明
- 批准号:
26461102 - 财政年份:2014
- 资助金额:
$ 15.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Minimally invasive response evaluation in vivo for the dual therapy of the angiogenesis inhibitors
血管生成抑制剂双重治疗的体内微创疗效评价
- 批准号:
23591763 - 财政年份:2011
- 资助金额:
$ 15.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ANGIOGENESIS INHIBITORS IN THE MULTIMODAL TREATMENT OF PEDIATRIC SOLID TUMORS
血管生成抑制剂在小儿实体瘤多模式治疗中的应用
- 批准号:
8309814 - 财政年份:2011
- 资助金额:
$ 15.97万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
7351352 - 财政年份:2008
- 资助金额:
$ 15.97万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
8002099 - 财政年份:2008
- 资助金额:
$ 15.97万 - 项目类别:
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors
针对炭疽毒素受体的新型血管生成抑制剂
- 批准号:
7615664 - 财政年份:2008
- 资助金额:
$ 15.97万 - 项目类别: